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Aims It is not known whether concomitant use of aspirin might attenuate the beneficial effects of mineralocorticoid
receptor antagonists (MRAs). The purpose of this subgroup analysis was to explore the interaction between baseline
aspirin treatment and the effect of eplerenone on the primary efficacy outcomes (composite of hospitalization
for heart failure or cardiovascular mortality), its components, and safety markers [estimated glomerular filtration
rate (eGFR), systolic blood pressure (SBP), and serum potassium >5.5 mmol/L] in the Eplerenone in Mild Patients
Hospitalization and SurvIval Study in Heart Failure trial (EMPHASIS-HF).
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Methods
and results
Patients with chronic heart failure, reduced ejection fraction (HFREF), and mild symptoms were enrolled in
EMPHASIS-HF. We evaluated baseline characteristics according to aspirin use. We explored the interaction between
aspirin and eplerenone, using Cox proportional hazards models providing adjusted hazard ratios (HRs) with 95%
confidence intervals (CIs) and P-values for interaction. Of the 2737 patients randomized, 1605 patients (58.6%) were
taking aspirin. The beneficial effects of eplerenone on the primary endpoint were similar in patients not treated
(adjusted HR 0.59, 95% CI 0.46–0.75) or treated (adjusted HR 0.71, 95% CI 0.59–0.87) with aspirin at baseline
(interaction P-value= 0.19). We did not observe any significant modification of the safety markers by aspirin that was
clinically meaningful.
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Conclusion Aspirin use in patients with chronic systolic heart failure and mild symptoms did not substantially reduce the overall
beneficial effects of the MRA eplerenone contrary to what has been described in some studies with ACE inhibitors.
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Introduction
The potential antagonistic effect between aspirin and ACE
inhibitors has been an area of intense debate following publication
of a pre-specified subgroup analysis of the Studies of Left Ventricu-
lar Dysfunction (SOLVD) trial.1 Several studies provided conflicting
data on the clinical significance of this potential detrimental inter-
action in heart failure (HF) patients.2–7 Mechanistically, however,
such an interaction is possible given the potential role of stimula-
tion of vasodilator prostaglandins in the action of ACE inhibitors
and the inhibitory action of aspirin on the production of these
substances.
Mineralocorticoid receptor antagonists (MRAs) reduced mor-
bidity and mortality in several landmark studies.8–10 Pharmaco-
logical interactions between aspirin and the MRA spironolactone
have been described previously.11–13 Spironolactone was reported
to increase reno-medullary prostaglandin synthesis.11 Aspirin has
been reported to decrease the natriuretic effect of spironolactone,
possibly through active competition for the renal tubular secretion
mechanism or mineralocorticoid receptor blockade.11–13 There-
fore, a clinically meaningful adverse interaction between aspirin and
MRAs is theoretically plausible and could potentially lead to detri-
mental outcomes in HF patients. However, the potentially delete-
rious impact of aspirin–MRA counteraction on clinical outcomes
(if any) is uncertain, especially with eplerenone, a selective MRA.
While there was no apparent effect of aspirin use at baseline on
the beneficial effects of eplerenone in patients with early post-acute
myocardial infarction (AMI) complicated by LV systolic dysfunc-
tion (LVSD) and HF (EPHESUS),14 its effect on the risk/benefit
of eplerenone in patients with chronic HF and a reduced ejec-
tion fraction (HFREF) with mild symptoms has not been investi-
gated. It is therefore of both therapeutic and mechanistic interest
to evaluate the impact of concomitant administration of aspirin to
patients with HF who are receiving MRAs. To address this, we con-
ducted a pre-specified subgroup analysis on the safety and efficacy
of eplerenone according to baseline aspirin use in EMPHASIS-HF.
Methods
Study design and patient population
The design and primary results of EMPHASIS-HF have been reported
elsewhere.10,15 Briefly, patients with NYHA class II symptoms, who
were >55 years of age, with an EF of no more than 30% (or
30–35% if QRS duration >130 ms), as well as receiving standard
background HF therapy, comprising ACE inhibitors, an ARB (or
both), and a beta-blocker (BB) at recommended or maximal tol-
erated doses, and had been hospitalized for cardiovascular reasons
within the past 6 months (or had a plasma BNP of at least 250 pg/mL
or NT-proBNP ≥500 pg/mL for males and ≥750 pg/mL for females
within 15 days prior to randomization) were eligible for enrolment.
Investigators were encouraged to up-titrate patients to the high-
est stable doses of these therapies before randomization into the
EMPHASIS-HF study. Key exclusion criteria included an indication for
MRA treatment according to current HF guidelines, need for adjunc-
tive potassium-sparing diuretic therapy, serum potassium >5.0 mmol/L



















































































.. (eGFR) <30 mL/min/1.73 m2 within 24 h prior to randomization, and
any other pre-existing and ongoing significant co-morbid condition.
Patients were randomized to receive either eplerenone (up to 50 mg
daily) or placebo, in addition to recommended therapy. Patients were
seen 4 weeks after randomization and then every 4 months during
trial follow-up. The primary outcome was the composite of death
from cardiovascular causes or HF hospitalization. The trial was stopped
prematurely for overwhelming benefit, after a median follow-up period
of 21 months.
Patients analysed
The analysis included all randomized patients in EMPHASIS-HF. Aspirin
use was determined from the screening and baseline concomitant drug
treatment pages of the study case report form.
Statistical analysis
We compared the characteristics of patients according to aspirin use at
baseline. P-values were calculated using a 𝜒2 test or two-sample t-test
as appropriate. Event rates for the primary composite outcome and its
components were calculated according to study treatment assignment
(eplerenone or placebo) and baseline aspirin use. Efficacy analyses were
performed using a multivariable Cox proportional hazards models,
including treatment, baseline aspirin, and treatment by baseline aspirin
interaction. Models were also adjusted for the EMPHASIS-HF risk
score.16 The effect of eplerenone (and any interaction with aspirin)
on safety markers including eGFR, systolic blood pressure (SBP), and
serum potassium >5.5 mmol/L were also investigated. Comparisons
at each visit were made using linear regression models adjusting for
baseline values. Overall comparisons were made using mixed models
adjusting for baseline values.
All P-values were two sided, and P< 0.05 was considered statistically





The baseline characteristics of the patients, based on aspirin use,
are presented in Table 1. Of the 2737 patients randomized, 1605
patients (58.6%) were taking aspirin. Patients not taking aspirin
were more likely to have atrial fibrillation/flutter, as well as to be
receiving treatment with digoxin and oral anticoagulants compared
with aspirin users (P< 0.0001). Patients on aspirin therapy were
more likely to be overweight and have a history of hypertension,
diabetes, coronary heart disease, and coronary revascularization.
Aspirin users were also more likely to be treated with an ACE
inhibitor/ARB and BB. Of note, an ACE inhibitor/ARB and a BB
were used in >85% of patients.
Study outcomes
The primary and secondary endpoints according to treatment and
baseline aspirin use are summarized in Figures 1 and 2. Baseline
treatment with aspirin did not significantly attenuate the effect of
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Table 1 Association between baseline aspirin use and
other baseline variables in EMPHASIS-HF
Baseline aspirin use P-valuea





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Treatment group, n (%)
Placebo 821 (51.2) 552 (48.8)
Eplerenone 784 (48.9) 580 (51.2) 0.22
Sex, n (%)
Male 1261 (78.6) 866 (76.5)
Female 344 (21.4) 266 (23.5) 0.20
Age, n (%)
<75 years 1222 (76.1) 858 (75.8)
75+ years 383 (23.9) 274 (24.2) 0.84
Mean (SD), years 68.7 (7.6) 68.6 (7.8) 0.81
Vital signs, mean (SD)
SBP, mmHg 125.3 (16.5) 122.5 (17.3) <0.0001
DBP, mmHg 75.0 (10.1) 74.2 (10.4) 0.055
Heart rate, b.p.m. 72.1 (14.9) 75.4 (16.2) <0.0001
Race, n (%)
White 1330 (82.9) 937 (82.8)
Black 34 (2.1) 33 (2.9)
Asian 190 (11.8) 127 (11.2)
Other 51 (3.2) 35 (3.1) 0.58
Region, n (%)
Asia/Middle East/Africa 228 (14.2) 152 (13.4)
East Europe 595 (37.1) 316 (27.9)
South/North America 219 (13.6) 127 (11.2)
West Europe/Australia 563 (35.1) 537 (47.4) <0.0001
Heart failure diagnosis, n (%)
Ischaemic 1295 (80.7) 591 (52.2)
Non-ischaemic 307 (19.1) 539 (47.6)
Unknown 3 (0.2) 2 (0.2) <0.0001
Days since index event, n (%)
0–41 681 (48.5) 481 (51.6)
42+ 724 (51.5) 452 (48.5) 0.14
Co-morbidities, n (%) yes
Previous HFH 819 (51.0) 620 (54.8) 0.051
Previous MI 992 (61.8) 389 (34.4) <0.0001
Angina 848 (52.8) 341 (30.2) <0.0001
Ischaemic stroke 116 (7.3) 79 (7.0) 0.83
Overweight (BMI 25+) 1147 (71.9) 759 (67.4) 0.012
Hypertension 1142 (71.2) 677 (59.9) <0.0001
Diabetes 530 (33.0) 329 (29.1) 0.029
CABG 351 (21.9) 165 (14.6) <0.0001
PCI 455 (28.4) 141(12.5) <0.0001
Atrial fibrillation/flutter 322 (20.1) 522 (46.2) <0.0001
Medications, n (%) yes
Beta-blockers 1414 (88.1) 956 (84.5) 0.006
Diuretics 1340 (83.5) 972 (85.9) 0.091
ACE inhibitor 1331 (82.9) 870 (76.9) <0.0001
ARB 283 (17.6) 238 (21.0) 0.026
ACE inhibitor or ARB 1533 (95.5) 1057 (93.4) 0.014
Digoxin 240 (15.0) 276 (24.4) <0.0001
Oral anticoagulants 136 (8.5) 356 (31.5) <0.0001
BMI, body mass index; DBP, diastolic blood pressure; HFH, heart failure hospi-
talization; MI, myocardial infarction; SBP, systolic blood pressure.
aP-value from 𝜒2 test for categorical variables or two-sample t-test for compar-




















































































. eplerenone on the primary endpoint (either a first hospitalization
for HF or a cardiovascular death). The adjusted hazard ratio
(HR; eplerenone vs. placebo) was 0.59 [95% confidence interval
(CI) 0.46–0.75] in those not treated with aspirin compared with
0.71 (95% CI 0.59–0.87) in patients treated with aspirin (P for
interaction= 0.19).
Baseline treatment with aspirin did not significantly reduce the
effect of eplerenone on cardiovascular death. The adjusted HR for
cardiovascular death was 0.69 (95% CI 0.50–0.94) in those not
treated with aspirin compared with 0.86 (95% CI 0.67–1.12) in
patients treated with aspirin (P for interaction= 0.25).
There was borderline evidence that baseline treatment with
aspirin did modify the effect of eplerenone on HF hospitaliza-
tion. The adjusted HR for HF hospitalization was 0.48 (95% CI
0.35–0.65) in those not treated with aspirin compared with 0.69
(95% CI 0.54–0.87) in patients treated with aspirin (P for interac-
tion= 0.05).
Baseline treatment with aspirin did not significantly attenuate
the effect of eplerenone on all-cause mortality. The adjusted HR
for all-cause mortality was 0.69 (95% CI 0.52–0.92) in those not
treated with aspirin compared with 0.82 (95% CI 0.65–1.05) in
patients treated with aspirin (P for interaction= 0.34).
Safety markers
The mean change in eGFR from baseline in patients randomized
to eplerenone compared with placebo was −2.06 (95% CI −3.21
to −0.91; P< 0.001). eGFR in those not treated with aspirin was
reduced by −1.89 mL/min/1.73 m2 (95% CI −3.63 to −0.15) from
baseline compared with −2.13 mL/min/1.73 m2 (95% CI −3.66 to
−0.60) in patients treated with aspirin (P for interaction= 0.83)
(Table 2).
Figure 3 shows the mean change in SBP from baseline over the
37 months of follow-up. The mean change in SBP from baseline
in patients randomized to eplerenone compared with placebo was
−1.81 mmHg (95% CI −2.58 to −1.03; P< 0.001). SBP in those not
treated with aspirin was reduced by −1.28 mmHg (95% CI −2.41
to 0.06) from baseline compared with −2.17 mmHg (95% CI −3.17
to −1.16) in patients treated with aspirin (P for interaction= 0.26).
Patients randomized to eplerenone were more likely to have
potassium >5.5 mmol/L during the follow-up compared with those
receiving placebo (11.0% vs. 6.7%, P< 0.001). There was no evi-
dence of an interaction between aspirin and eplerenone in having
potassium >5.5 mmol/L at any point during follow-up (P for inter-
action= 0.46) (Table 3).
Discussion
The present findings showed that concurrent use of aspirin did not
attenuate the overall beneficial effects of eplerenone in patients
with chronic HF and mild symptoms. Although our results showed
that there was borderline evidence of concomitant use of aspirin
modifying the effects of eplerenone on the risk of hospitalization
for HF, the overall clinical benefits of eplerenone were preserved
among aspirin users. The clinical benefits of eplerenone were
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Figure 1 Kaplan–Meier cumulative incidence of the primary and secondary endpoints by baseline aspirin use and treatment. (A) Primary
endpoint [cardiovascular (CV) death/heart failure (HF) hospitalization]. (B) CV death. (C) HF hospitalization. (D) All-cause death.
obtained even though nearly all patients were also treated with
other effective pharmacological agents (i.e. ACE inhibitors/ARBs
and a BB). Our data showed that while eplerenone use was
associated with greater reductions in eGFR and SBP, and a higher
risk of hyperkalaemia, these changes appeared to be no different in
the presence of aspirin.
Prostaglandin I2 and prostaglandin E2 are potent vasodilators and
may play an important role in counteracting excessive vasoconstric-
tive effects of other neurohormonal pathways in HF patients.17,18
Mean circulating levels of these prostaglandins have been shown to
be 3–10 times higher in patients with severe congestive HF with
hyponatraemia, a marker of renin–angiotensin–aldosterone sys-
tem (RAAS) activation, compared with healthy individuals.18 While
the inhibitory action of aspirin on prostaglandin synthesis is well
documented, previous reports of aspirin decreasing the natriuretic
effect and reno-medullary prostaglandin synthesis of spironolac-
tone suggest that the impact of this interaction on the clinical
outcomes in patients with HF is worth investigating.
Concomitant CAD is the leading cause of systolic HF. More






























. Studies of Left Ventricular Dysfunction Treatment trial (SOLVD-T),
Candesartan in Heart failure: Assessment of Reduction in Mor-
tality and morbidity-Added (CHARM-Added), EMPHASIS HF,
and Prospective comparison of ARNI with ACEI to Determine
Impact on Global Mortality and morbidity in Heart Failure trial
(PARADIGM HF) were found to have an ischaemic aetiology.19
There is a widely held belief that aspirin has a protective role in
patients at increased risk of occlusive vascular events.20,21 Because
of these two factors, aspirin and MRAs are widely used together
in patients with HF.
The beneficial clinical effects of MRAs have been clearly demon-
strated in patients with moderate to severe HF (RALES), chronic
HF with mild symptoms (EMPHASIS-HF), and post-acute myocar-
dial infarction patients with LVSD and HF (EPHESUS). In these
trials, a large number of the patients had concomitant CAD and
were taking aspirin. Specifically, aspirin use rates in our study
were 58.6% compared with 88.5% in EPHESUS; and 36.5% in
RALES.8,14 Prior findings from EPHESUS subgroup analyses sug-
gested that the concomitant use of aspirin at baseline did not
significantly influence the beneficial effects of eplerenone in that
© 2016 The Authors
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Figure 2 Primary and secondary endpoints according to baseline aspirin use. CI, confidence interval; CV, cardiovascular; Eple, eplerenone;
HF, heart failure; HR, hazard ratio; Nos events (rate1), number of events (event rate per 100 person-years); Plac, placebo.
Table 2 Difference in mean change from baseline estimated glomerular filtration rate by treatment and aspirin use
All patients No aspirin Aspirin
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Visit Mean 95% CI P-value Mean 95% CI Mean 95% CI Interaction
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Month 5 −2.46 (−3.79 to −1.12) <0.001 −2.47 (−4.50 to −0.44) −2.36 (−4.15 to −0.58) 0.95
Month 13 −1.57 (−3.10 to −0.03) 0.046 −1.92 (−4.29 to 0.45) −1.28 (−3.31 to 0.75) 0.68
Month 21 −2.36 (−4.28 to −0.44) 0.016 −2.41 (−5.42 to 0.59) −2.36 (−4.88 to 0.16) 0.98
Month 29 0.43 (−1.88 to 2.750) 0.71 −0.68 (−4.38 to 3.02) 1.30 (−1.68 to 4.29) 0.40
Month 37 0.41 (−2.87 to 3.69) 0.80 −1.23 (−6.40 to 3.93) 1.21 (−3.11 to 5.52) 0.54
Month 42 0.66 (−5.24 to 6.55) 0.83 5.10 (−4.98 to 15.17) −2.05 (−9.64 to 5.53) 0.34
Month 48 −0.85 (−8.25 to 6.55) 0.82 2.28 (−6.73 to 11.30) −4.90 (−17.31 to 7.51) 0.30
Overall −2.06 (−3.21 to −0.91) <0.001 −1.89 (−3.63 to −0.15) −2.13 (−3.66 to −0.60) 0.83
CI, confidence interval.
study (death from any cause, P for interaction= 0.63; death from
cardiovascular causes or hospitalization for cardiovascular events,
P for interaction= 0.33).14
The data presented here confirm such findings, i.e. the addition
of eplerenone in patients already receiving standard HF therapy
as well as aspirin was well tolerated along with preserving the
substantial clinical benefits of eplerenone, albeit with borderline
evidence of a modified effect on hospitalization for HF. The
inhibitory effect of aspirin on prostaglandin synthesis does not off-














.. haemodynamic and remodelling changes were not evaluated in this
analysis; hence, we could not evaluate the presence (or absence)
of an interaction between prostaglandins and aldosterone in
cardiac remodelling processes in HF. In addition, our analysis could
not confirm whether aspirin attenuated the beneficial effect of
eplerenone on HF deaths.
Importantly, we did not observe any significant modification of
the safety markers by aspirin that was clinically meaningful. The
incidence of mild hyperkalaemia (serum potassium >5.5 mmol/L)
and mean change of SBP and renal function from baseline among
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Figure 3 Mean change of systolic blood pressure (SBP) from
baseline over the follow-up by treatment and aspirin use. (A)
Patients with baseline aspirin use. (B) Patients without baseline
aspirin use.
Table 3 Patients with potassium >5.5 mmol/L at any







. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All 237 (8.9%) 147 (11.0%) 90 (6.7%) P< 0.001
No aspirin 82 (7.4%) 50 (8.7%) 32 (6.0%)
Aspirin 155 (9.9%) 97 (12.7%) 58 (7.2%) P= 0.46a
aInteraction P-value.
aspirin users in the eplerenone group is similar to that of the overall
eplerenone group in our study and in EPHESUS.10,14,22
The EMPHASIS-HF trial was mainly conducted outside the USA.
While low-dose aspirin is likely to be preferred at sites located
outside the USA, high-dose aspirin (≥300 mg/day) is commonly
prescribed in the USA.23 The use of aspirin therapy during the
conduct of our study was not analysed. Moreover, we did not
determine the dosage of aspirin in this analysis, which may influence
the outcomes of our analysis, as observed by Guazzi et al. and
Meune et al.24,25 In both studies, aspirin effects on vascular tone and



















































































.. were suggested to be dose related. Combinations of a high dose
of aspirin (≥325 mg) with ACE inhibitors were observed to have
significantly altered arterial functional properties and led to higher
risk of death by 3% compared with patients who received a lower
dose of aspirin (≤160 mg). Hence, our findings of an increased
HF hospitalization rate with concomitant use of aspirin can be
seen as hypothesis-generating, and future studies may be needed to
evaluate whether the use of high-dose aspirin reduces the clinical
benefits of MRAs.
Our study had several potential limitations. This is a sub-
group analysis and therefore inadequately powered to evaluate
subgroup–treatment effect interaction. Unmeasured variations
could have confounded the findings. Since multiple comparisons
were performed, the findings could be by chance. In addition,
we only considered aspirin treatment at baseline for this analysis.
Finally, our results may not be applicable to all patients with mild
symptoms of HF, because, in order to be eligible for the study,
patients had to have additional factors known to increase cardio-
vascular risk, including age >55 years, in most cases an EF of no
greater than 30%, and a recent hospitalization for a cardiovascular
reason.
In conclusion, background aspirin use in patients with mild
symptoms of systolic HF does not offset the overall beneficial
effect of eplerenone. The adverse interaction previously reported
between aspirin and ACE inhibitors in patients with systolic HF in
some but not all studies does not appear to occur with eplerenone
in EMPHASIS-HF.
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